After failed cancer test, Tocagen slashes staff

Just last month, Tocagen posted a failed late-stage trial for its gene therapy attempt to boost survival in brain cancer and said it was seeking an “operational review.”

Review done, and the results are in: 65% of staffers will face the ax, leaving just 30 full-timers at the biotech by year’s end.